ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2022
What is the prevalence of hepatic steatosis on ultrasonography in patients followed for nephrolithiasis?
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 citations in OpenAlex.
- Association between triglyceride-glucose and fibrosis-4 indices and nephrolithiasis: a cross-sectional case-control study.Revista da Associacao Medica Brasileira (1992) · 2026Article
- Metabolic dysfunction associated steatotic liver and kidney stones: what is going on?Current opinion in nephrology and hypertension · 2025Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with non-alcoholic fatty liver disease (NAFLD) have higher prevalence of nephrolithiasis. The aim of the present study was to determine prevalence of hepatic steatosis on ultrasonography in nephrolithiasis patients.
methodsCharts of 318 consecutive nephrolithiasis patients seen in stone clinic between January and February 2018 were retrospectively reviewed. Ultrasound reports were reviewed for hepatic steatosis. Subsequent liver investigations were noted. Patients' demographic predictors of hepatic steatosis were identified using univariable logistic regression models.
resultsA total of 162 patients was included, of which 76 (46.9%) were found to have hepatic steatosis and 22 (13.6%) were found to have moderate-to-severe hepatic steatosis. Median followup was 2.03 years. Predictors of hepatic steatosis included higher body mass index and smoking (both p<0.05). Progression of fatty liver on ultrasound was noted for 13 (17.1%) and regression was noted for two (2.6%). Of the 16 patients with a Fibrosis-4 (FIB-4) score, four (25.0%) patients required further investigation and 12 (75.0%) were unlikely to have advanced fibrosis. Of 12 patients who underwent fibroscan, one (8.3%) had both fibrosis and cirrhosis, two (16.7%) fibrosis only, and two (16.7%) moderate-to-severe steatosis.
conclusionsHepatic steatosis on ultrasound followup of nephrolithiasis patients is common, especially in smokers and overweight patients. Current recommendations suggest that primary care physicians calculate a FIB-4 score upon the detection of hepatic steatosis on ultrasound. The decision to refer to hepatology for a corroborative fibroscan is then based on the FIB-4 score.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.